title: Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients.
authors.affiliation: Universitätsklinikum Dresden, Dresden, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Platzbecker
authors.affiliation: Universitätsklinikum Leipzig, Leipzig, Germany.
authors.forename: H K
authors.initials: HK
authors.lastname: Al-Ali
authors.affiliation: Universitätsklinikum Düsseldorf, Düsseldorf, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Gattermann
authors.affiliation: Universitätsmedizin Göttingen, Göttingen, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Haase
authors.affiliation: Universitätsklinikum Bonn, Bonn, Germany.
authors.forename: V
authors.initials: V
authors.lastname: Janzen
authors.affiliation: Medizinische Hochschule Hannover, Hannover, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Krauter
authors.affiliation: Klinikum rechts der Isar der Technischen Universität München, München, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Götze
authors.affiliation: Universitätsklinikum Ulm, Ulm, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Schlenk
authors.affiliation: Universitätsmedizin Mannheim, Mannheim, Germany.
authors.forename: F
authors.initials: F
authors.lastname: Nolte
authors.affiliation: Charité Berlin, Berlin, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Letsch
authors.affiliation: Universitätsklinikum Frankfurt, Frankfurt, Germany.
authors.forename: O G
authors.initials: OG
authors.lastname: Ottmann
authors.affiliation: Universitätsklinikum Düsseldorf, Düsseldorf, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Kündgen
authors.affiliation: Universitätsklinikum Freiburg, Freiburg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Lübbert
authors.affiliation: Universitätsklinikum Düsseldorf, Düsseldorf, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Germing
authors.affiliation: Universitätsklinikum Dresden, Dresden, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Wermke
authors.affiliation: Novartis Pharma GmbH Nürnberg, Nürnberg, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Reinhard
authors.affiliation: Novartis Pharma GmbH Nürnberg, Nürnberg, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Weiss
authors.affiliation: Novartis Pharma GmbH Nürnberg, Nürnberg, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Lieder
authors.affiliation: Universitätsklinikum Dresden, Dresden, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Ehninger
authors.affiliation: Novartis Pharma GmbH Nürnberg, Nürnberg, Germany.
authors.forename: O
authors.initials: O
authors.lastname: Leismann
authors.affiliation: Marienhospital Düsseldorf, Düsseldorf, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Giagounidis
mesh_terms: D000284:Administration, Oral; D001803:Blood Transfusion; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use*; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D000077767:Panobinostat
chemical_list: D006877:Hydroxamic Acids; D007211:Indoles; D004921:Erythropoietin; D000077767:Panobinostat